Skip to main content
Premium Trial:

Request an Annual Quote

Pluvita Nabs Majority Stake in Diogenics

WASHINGTON, DC, Oct. 3 – Pluvita, a drug-discovery and development company, has acquired a majority stake in Diogenics, a privately held genomic firm, the companies said on Wednesday.

The acquisition, for an undisclosed amount, was designed to allow Pluvita to combine its bioinformatics, information management, and clinical databases with Diogenics’ wet-lab capabilities, model systems, and intellectual property assets, Pluvita said in a statement.  

“This is a key validation from a research organization of Pluvita’s unique model to accelerate the drug discovery and development process,” the company said before the start of the Biotechnology Industry Organization venture capital forum here this week, where it is participating. “The Diogenics acquisition is a collaborative partnership and serves as proof-of-principle of our unique approach to target and lead identification and optimization,” Pluvita CEO Gary J. Kurtzman added in a statement.

Diogenics, of Irvine, Calif., identifies and validates clinically relevant gene and protein targets in steroid hormone-responsive diseases, including prostate cancer, BPH, breast cancer, ovarian cancer, and other reproductive diseases, according to Pluvita. 

Beside Diogenics’ wet lab capabilities and intellectual property assets, Bethesda, Md.-based Pluvita will acquire a scientific team experienced in molecular biology, microarray technology, protein expression, immunology, reproductive biology, vaccine delivery, functional genomics, proteomics, structural biology, and bioinformatics, Pluvita said. 

The Diogenics acquisition is the first in a series of strategic relationships Pluvita plans over the next year, according to Pluvita.

The Scan

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.

Plan Rebuffed

The Associated Press reports China has rejected the World Health Organization's proposal to include the lab-leak theory in the next phase of its investigation into the origins of SARS-CoV-2.